Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference
Rhea-AI Summary
Caribou Biosciences (Nasdaq: CRBU) announced that its management team will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026 at 12:30 p.m. ET in New York.
A live webcast and replay will be available for at least 30 days on the Events page of Caribou’s website.
Positive
- None.
Negative
- None.
News Market Reaction – CRBU
In the May 14 session, CRBU gained 0.94%, reflecting a mild positive market reaction. Argus tracked a peak move of +15.4% during that session. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 12 | Scientific conference update | Positive | +0.0% | Plans oral presentations on vispa-cel and CB-011 at EHA 2026. |
| May 07 | Earnings and pipeline | Positive | +3.2% | Q1 2026 results with FDA alignment on ANTLER-3 and RMAT for CB-011. |
| May 05 | Investor conference | Neutral | +1.0% | Announcement of participation in BofA 2026 Health Care Conference. |
| Mar 31 | Regulatory designation | Positive | +10.5% | FDA grants RMAT designation to CB-011 based on phase 1 data. |
| Mar 05 | Earnings and pipeline | Positive | +6.4% | FY2025 results with reduced expenses and strong cash position into 2H 2027. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Stock has generally reacted positively or neutrally to company updates, including regulatory milestones, earnings, and conference participation.
Over recent months, Caribou Biosciences reported multiple milestones, including RMAT designation for CB-011 and detailed FY2025 and Q1 2026 financials with cash runway into 2H 2027. Earnings updates highlighted reduced expenses and narrowed losses, while scientific meetings and conferences showcased vispa-cel and CB-011 trial progress. These prior events often saw modest positive price reactions. Today’s BioConnect conference participation fits a pattern of ongoing investor outreach alongside clinical and regulatory advancement.
Key Terms
crispr medical
genome-editing medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BERKELEY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Caribou’s management team will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, at 12:30pm ET in New York, New York.
For more information and a link to the webcast, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event.
About Caribou Biosciences, Inc.
Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Caribou’s chRDNA genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Follow the company @CaribouBio and visit www.cariboubio.com.
Caribou Biosciences, Inc. contact:
Peggy Vorwald, PhD
investor.relations@cariboubio.com
media@cariboubio.com
